More than 80% of women experience some symptoms around menopausei<\/sup><\/i><\/p>\n BOCA RATON, Fla.–(BUSINESS WIRE<\/a>)– \nMany people are aware of common menopause symptoms like hot flashes, which impact 85% of menopausal womeniii<\/sup>, but vulvar and vaginal atrophy (\u201cVVA\u201d), a condition experienced by more than half of menopausal women, is rarely discussed. While VVA causes symptoms like vaginal dryness, burning, itching, recurrent urinary tract infections (\u201cUTIs\u201d) and painful sex, 81% of these women are unaware that VVA is a medical conditioniv<\/sup>.\n<\/p>\n \n\u201cWhile women today are prioritizing their health more than ever before, menopause continues to be misunderstood and is rarely discussed,\u201d said Kristen Landon, Senior Vice President, Marketing, TherapeuticsMD. \u201cAt TherapeuticsMD, we want to change how menopause is portrayed in society and to help educate people about these naturally occurring changes to a woman\u2019s body during this life stage. The only way to do that is to help normalize menopause, ensure that women know they are not alone, and inspire them to feel comfortable to speak up and take action. This Menopause Awareness Month, we want to encourage women to Take Pause and give their bodies, including their vaginas, the care and love they deserve.\u201d\n<\/p>\n \nAs part of the Take Pause initiative, TherapeuticsMD is distributing a series of educational videos and \u201cpausable\u201d social posts on the IMVEXXY\u00ae (estradiol vaginal inserts) Facebook page<\/a>. This important information aims to reduce the stigma associated with menopause symptoms like painful sex, and to educate women on available treatment options, including IMVEXXY.\n<\/p>\n \nThrough the Take Pause initiative and our recent Long May She REIGN Campaign<\/a>, TherapeuticsMD is committed to raising awareness of the impact of menopause and educating women about available treatment options. Women can learn more about moderate to severe painful sex due to menopause at IMVEXXY.com and moderate to severe hot flashes at BIJUVA.com.\n<\/p>\n IMVEXXY (estradiol vaginal inserts) Important Risk Information<\/span><\/b><\/p>\n USE<\/b><\/p>\n \nIMVEXXY is a prescription medicine that contains an estrogen hormone in a vaginal insert. It is used after menopause to treat moderate to severe painful intercourse, a symptom of changes in and around your vagina, due to menopause.\n<\/p>\n IMPORTANT RISK INFORMATION<\/b><\/p>\n MOST IMPORTANT INFORMATION YOU SHOULD KNOW ABOUT IMVEXXY (an estrogen hormone)<\/b><\/p>\n DO NOT USE IF YOU<\/b><\/p>\n WARNINGS<\/b><\/p>\n Tell your healthcare provider about all of your medical conditions, including if you:<\/b><\/p>\n Tell your healthcare provider about all the medicines you take.<\/b><\/p>\n \nIMVEXXY may affect the way other medicines work, and other medicines may affect how IMVEXXY works.\n<\/p>\n WHEN USING IMVEXXY YOU MAY HAVE<\/b><\/p>\n The risk information provided here is not complete. To learn more, talk about IMVEXXY with your healthcare provider or pharmacist. The FDA-approved product labeling can be found at IMVEXXY.com\/pi.pdf<\/a>.<\/b><\/p>\n BIJUVA\u00ae (estradiol and progesterone) Important Risk Information<\/span><\/b><\/p>\n IMPORTANT RISK INFORMATION<\/b><\/p>\n Most important information you should know about BIJUVA (a combination of estrogen and progestogen):<\/b><\/p>\n DO NOT USE BIJUVA IF YOU <\/b><\/p>\n WARNINGS<\/b><\/p>\n Ask a doctor before use if you:<\/b><\/p>\n Tell your doctor or pharmacist about all the medicines you take, <\/b>including prescription and over-the-counter medicines, vitamins, and herbal supplements.\n<\/p>\n WHEN USING BIJUVA, YOU MAY HAVE<\/b><\/p>\n \n\u25cf Breast tenderness \u25cf Headache \u25cf Vaginal bleeding \u25cf Vaginal discharge \u25cf Pelvic pain\n<\/p>\n Call your doctor right away if you get any of the following warning signs:<\/b><\/p>\n USE<\/b><\/p>\n \nBIJUVA is a prescription medicine that contains two hormones, an estrogen and a progestogen. BIJUVA is used after menopause to reduce moderate to severe hot flashes<\/b> in women with a uterus.\n<\/p>\n The risk information provided here is not complete. To learn more, review the BIJUVA Patient Information and talk about BIJUVA with your healthcare provider or pharmacist. The FDA-approved product labeling, including Patient Information, can be found at BIJUVA.com\/pi.pdf<\/a>.<\/b><\/p>\n You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch<\/a> or call 1-800-FDA-1088. You may also report side effects to TherapeuticsMD at 1-888-228-0150.<\/b><\/p>\n About TherapeuticsMD<\/b><\/p>\n \nTherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com<\/a> or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.\n<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nThis press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD\u2019s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management\u2019s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company\u2019s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company\u2019s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company\u2019s ability to maintain or increase sales of its products; the company\u2019s ability to develop and commercialize IMVEXXY\u00ae, ANNOVERA\u00ae, and BIJUVA\u00ae and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; whether the company will be able to successfully divest, or obtain an investment in, its vitaCare business and how the proceeds that may be generated by any such divestiture or investment will be utilized; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company\u2019s current or future approved products or preclude the approval of the company\u2019s future drug candidates; whether the FDA will approve the lower dose of BIJUVA; the company\u2019s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company\u2019s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company\u2019s licensees to commercialize and distribute the company\u2019s products; the ability of the company\u2019s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company\u2019s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company\u2019s common stock and the concentration of power in its stock ownership.\n<\/p>\n i<\/sup> Sussman et al. Prevalence of menopausal symptoms among mid-life women: findings from medical records. BMC Women\u2019s Health. 2015 15:58. doi: 10.1186\/s12905-015-0217-y.\n<\/p>\n ii<\/sup> Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE survey. Clin Med Insights Reprod Health. 2014;8:23-30\n<\/p>\n iii<\/sup> Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Woode DE; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. Endocr Pract. 2011 Nov-Dec;17 Suppl 6:1-25. doi: 10.4158\/ep.17.s6.1. PMID: 22193047.\n<\/p>\n iv<\/sup> Kingsberg SA et al. The Women\u2019s EMPOWER Survey: Identifying Women\u2019s Perceptions on Vulvar and Vaginal Atrophy and Its Treatment J Sex Med. 2017;14:413-424.\n<\/p>\n \nTXMD-20060\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210902005272\/en\/<\/a><\/span><\/p>\n
\nThis September, TherapeuticsMD, Inc., an innovative women\u2019s healthcare company (NASDAQ: TXMD), is recognizing Menopause Awareness Month, as it aims to empower the 64 million women in the U.S. currently in menopauseii<\/sup>. To celebrate this month and all menopausal women, TherapeuticsMD encourages people to Take Pause and learn about menopause.\n<\/p>\n\n
\n
\n
\n
\n
\n
\n
\n
\n
<\/p>\n